Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
By L. Baden, Hana M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. Spector, N. Rouphael, C. Creech and 27 more. New England Journal of Medicine, 2020
8,213 citations recorded by the source corpus.
Abstract Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. Methods This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. Results The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. Conclusions The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.)
Subfields: Genetics, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1e911af6e49fca0471e5c079d2da4d2a98c71c31
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Infectious Diseases
In Molecular Biology
Citations in the corpus
- Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021, neutral): “Ultra‐Orthodox Jewish 24,343 (3) 24,343 (3) 20,864 (12) 20,864 (12)”
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2021, neutral): “These SARS-CoV-2 vaccines have been remarkably successful in inducing neutralizing humoral and cellular immunity and, more importantly, reducing COVID-19 infections, hospitalizations, and deaths in clinical trials (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021) and during rapid worldw”
- Vaccine adjuvants: mechanisms and platforms (2023, background): “These two mRNA vaccines have made a significant contribution to the fight against COVID-19.(269,270)”
- mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern (2021, methodology): “Furthermore, there may be differences in immunity generated by mRNA vaccination versus infection, as memory B cells 6 months post-vaccination were qualitatively superior at binding VOCs compared to memory B cells 6 months after recovering from mild COVID-19.”
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. (2021, background): “During a median (range) follow-up duration of 77 (1-121) days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (12.”
- Adaptive immunity to SARS-CoV-2 and COVID-19 (2021, neutral): “94% efficacy at protection from COVID-19 was reported, with 196 total cases to evaluate in the FDA review (Baden et al., 2020).”